Many health care providers protest that their dealings with health insurers and managed care plans are one sided – that too much power is on one side of the table. Some payors are concerned that in some instances physicians or other providers collude to frustrate competition and artificially drive up prices.

Today’s health antitrust battlelines and this teleconference reflect these concerns. We focus today on part of this equation -- antitrust treatment of physician joint contracting activity, and in particular on the intersection of price fixing and physician network activity.
Antitrust enforcement authority over physician contracting is divided in many ways. At the federal level, enforcement authority is shared. The Federal Trade Commission ("FTC") has antitrust enforcement authority under the FTC Act. The Department of Justice ("DOJ") has antitrust enforcement authority under the Sherman Act.

States also have antitrust enforcement authority. State attorneys general enforce state antitrust laws and act as parens patriae under federal law. In addition, private plaintiffs have the ability to bring civil, treble damage actions. Employers and employer coalitions, consumers, and HMOs and other payors are all potential plaintiffs.

The antitrust laws prohibit agreements in restraint of trade. Agreements necessarily require multiple actors; under the antitrust laws, a single entity cannot agree with itself. Some agreements – such as price fixing, allocation of customers, certain tie-ins or group boycotts – are so inherently anticompetitive that they are deemed illegal on a per se basis. Other agreements must be “unreasonable” in terms of their competitive effects. Price-fixing agreements among competitors are per se illegal. The rule was applied by the Supreme Court in Arizona v. Maricopa County Medical Society, 457 U.S. 332 (1982) (striking down maximum fee schedule agreed to by members of a medical foundation).
PHYSICIAN NEGOTIATIONS

Physicians and other health care professionals are facing increasing marketplace pressures, from managed care, altered reimbursement rules in government programs, and their numerous peers. They perceive that payors have an unfair advantage and use “take it or leave it” tactics. However, when physicians or other providers seek to join together to better their bargaining position they can run into antitrust trouble.

Courts have expressed some sympathy for health care professionals dealing with payors, but have not relaxed the basic antitrust proscription against price fixing. In a criminal antitrust prosecution, United States v. Alston, 974 F.2d 1206 (9th Cir. 1992), dentists were accused of conspiring to force increases in co-payment fees payable by health plans. They were proven to have met to discuss fees, agreed on the higher fees to be sought, and to have mailed identical letters demanding higher fees. In remanding a case back to the trial court, the Court of Appeals commented:

[Health care providers who must deal with consumers indirectly through plans . . . face an unusual situation that may legitimate certain collective actions. Medical plans serve, effectively, as the bargaining agents for large groups of consumers; they use the clout of their consumer base to drive down health care service fees. Uniform fee schedules - anathema in a normal, competitive market - are standard operating procedure when medical plans are involved. In light of these departures from a normal competitive market, individual health care providers are entitled to take some joint action (short of price fixing or a group boycott) to level the bargaining imbalance created by the plans and provide meaningful input into the setting of the fee schedules.]
Thus health care providers might pool cost data in justifying a request for an increased fee schedule. . . . Providers might also band together to negotiate various other aspects of their relationship with the plans such as payment procedures, the type of documentation they must provide, the method of referring patients and the mechanism for adjusting disputes. Such concerted actions, which would not implicate the per se rule, must be carefully distinguished from efforts to dictate terms by explicit or implicit threats of mass withdrawals from the plans. . . .

974 F.2d at 1214 (emphasis added). The tension between letting providers have a voice in the process and permitting cartel activity can be seen in this language.

The antitrust enforcement agencies have attempted to strike an appropriate balance. They have continued to bring antitrust cases against conduct that they find to run seriously afoul of the antitrust laws, as they have for more than twenty years. Indeed, in the last year or two, there has been an upswing in enforcement activity, particularly at the FTC. Numerous consent agreements and complaints target alleged physician combinations to suppress price competition and raise prices that lack plausible joint venture or other legal rationales.¹ At the same time, the agencies have issued policy statements, as

---

well as advisory opinions, to help clarify application of the antitrust laws to health care industry activities. This guidance has stressed the joint price-setting by competitors is not necessarily illegal where it is ancillary to a bona fide and competitively meaningful joint venture or other productive collaborative activity.

SAFETY ZONE FOR FINANCIALLY INTEGRATED PHYSICIAN NETWORKS

In their 1996 statements of health care enforcement policy, http://www.ftc.gov/reports/hlth3s.htm, the agencies specifically addressed physician network joint ventures. The agencies explained that a physician controlled network organization would have "safety zone" protection where it involves no more than 30% of physicians in any single specialty in a geographic

market and physicians are integrated, such as through financial risk sharing; there is a 20% safety zone limit where physicians are exclusive with network entity.

   Indicia of non-exclusivity:

   (1) that viable competing networks or plans with adequate provider participation currently exist in the market;

   (2) that providers in the network actually participate in other networks or contract individually with health benefits plans, or there is other evidence of their willingness and incentive to do so;

   (3) that providers in the network earn substantial revenue outside the network;

   (4) the absence of any indications of significant departicipation from other networks in the market;

   (5) the absence of any indications of coordination among the providers in the network regarding price or other competitively significant terms of participation in other networks or plans.

   Where the percentage of doctors in network exceeds the safety zone threshold, legality depends on market impact, including assessment whether the
network serves as a competitive stimulus to the market, or a blockade against competing networks or penetration by managed care.\(^2\)

The agencies have provided examples of risk-sharing payment arrangements, such as percentage of premium revenue or global case rate methodologies, in addition to capitation and withhold arrangements.\(^3\)

---

\(^2\) The guidelines also provide helpful clarification to provider networks that enter into risk-sharing arrangements but also would like the flexibility to enter into some non-risk sharing arrangements without strictly adhering to the so-called "messenger model." The guidelines basically conclude that rule of reason analysis is appropriate for a network's fee-for-service payer arrangements, provided that a "substantial majority" of the network's contracting arrangements with payors include risk sharing and the network actively seeks to manage the provision of provider services in its fee-for-service contracts, using the same types of quality and cost management for its fee-for-service enrollees as it does for its risk-based enrollees.

On the other hand, problems can arise where a joint venture network is set up, anticipating widespread risk contracting, and a little fee for service business "on the side". Counsel should be alert to the possibility that fee-for-service business, and the size of the provider panel may expand greatly, while the risk business is a non-starter, and quality improvement and case management programs remain inchoate or "on paper only".

---

\(^3\) How much integration is enough? When are providers sufficiently integrated that price-related activities will not be viewed as per se illegal, or where potential anticompetitive aspects of price agreements will be outweighed by potential efficiency or other competitive benefits? No clear boundaries. Focus can be on whether risk sharing features are likely to engender change in provider behavior -- greater focus on cost containment, or improved quality of care within defined budgets, for example.

However, counsel should be wary of too intensive a search for boundaries of the per se rule, distracting from a broader assessment of the overall competitive character of the conduct in question -- whether the program is an effort to beat or keep up with the competition, or to establish an innovative delivery or financing vehicle, or, in contrast, to create a blockade to prevent competition or to forge a "united front" scheme.

Mere existence of withholds or bonus provisions not enough. Sometimes risk features seem "stapled" on by lawyers to justify price fixing. Inquiry might be whether price setting activity is incidental to joint venture, or whether "joint venture" features are mere appendages to price fixing arrangement.

A risk sharing formulation, in and of itself, might not definitively establish the legitimacy of a joint undertaking, either in terms of per se applicability or outcome of rule of reason analysis. Have structures been created through which the participating physicians can jointly respond to the incentives for cost consciousness created by the withhold and bonus provisions? Are there quality improvement or practice protocol programs? Involvement of physician network in oversight of utilization patterns? If such integration or collaborative activity is lacking, it may be less apparent that joint venture is more than a dressed up price agreement or that the arrangement's benefits outweigh potential anticompetitive effects. Collateral restraints in the arrangement, such as "rights of first refusal" requiring physicians to bring all managed care contracting opportunities to the venture first, may also tip the balance towards a potential antitrust violation.
CLINICAL INTEGRATION

The guidelines also explain that a provider network that achieves significant clinical coordination and integration among its members might also be able to negotiate managed care rates, even in the absence of capitation or another risk-sharing payment mechanism, under the antitrust rule of reason.\(^4\)

The change does not, however, open the doors to price fixing agreements by loosely organized networks that function as contracting entities without significant clinical or other operational integration among the members.

Significant integration can generally be evidenced by "the network implementing an active and ongoing program to evaluate and modify practice patterns by the network's physician participants and create a high degree of interdependence and cooperation among the physicians to control costs and ensure quality." Those provider network entities that do not undertake significant operational activity, beyond credentialing, participation in peer review, and

\(^4\) The statements also explain how the agencies analyze network ventures that are subject to "rule of reason" treatment. First, the agencies define the relevant geographic market and the relevant "product" market, and the market "concentration" of the joint venture activities. Second, the agencies evaluate the competitive effects of the physician joint venture, such as whether the joint venture will have the market position to raise prices, or whether the venture is likely to have "spillover" effects in the physicians' non-venture activities.

Third, the agencies will evaluate the impact of any procompetitive efficiencies that result from the network joint venture, and weigh them against the likely anticompetitive effects. However, the guidelines stress that claims of efficiency, even if substantiated, will not be justified if they could be achieved by less restrictive means that are practical and feasible under the market conditions faced by the providers. Likewise, if anticompetitive effects are unlikely to result from the venture, the agencies will not require the same degree of proof of efficiencies that they might with a more restrictive venture.

Finally, the agencies will evaluate any "collateral agreements," such as an agreement among participating physicians to give the network the right of first refusal to contract with any managed care plan that seeks an agreement with a participating physician, and other similar restraints. Normally, such collateral agreements must be necessary to the success of the venture in order to be considered defensible.
marketing, likely would not meet the rule of reason integration threshold described in the new statements.

A credentialing program and a peer review upon complaint program also likely are not enough. The focus would be on whether there is activity to manage the care being provided, and that the activity is substantial enough that there is a logical connection between the program's ability to succeed in the market and the venture's being able to establish the price terms on which the network's services will be sold, including but not limited to the health care services of the participating providers.

Are practice protocols being developed and applied? Is there a common case management or management information system being put in place? Can the network demonstrate changes in practice patterns resulting from its oversight programs?

The clinical integration approach is exemplified in the FTC staff advisory opinion issued to the Medsouth multispecialty physician IPA in Colorado. The FTC Bureau of Competition staff advised MedSouth that the staff does not intend to challenge MedSouth's proposed collective negotiation of payor contracts on behalf of members who participate in its clinical resource management program. (Feb. 19, 2002).

The MedSouth advisory opinion is the first written guidance issued by the FTC addressing in depth the amount and nature of clinical integration necessary to permit otherwise independent physician practices to collectively negotiate fees without violating federal price fixing prohibitions since the 1996 update to the
Statements of Antitrust Enforcement Policy in Health Care issued jointly by the FTC and the Antitrust Division of the U.S. Department of Justice.

Under MedSouth's proposal, all physicians who are members of MedSouth physician practices will be required to participate in MedSouth's proposed clinical integration program. The program will have two major components. First, the physicians will use an electronic data record system that will permit them to access and share clinical data related to their patients, such as patient records, lab reports, treatment plans and prescription information. Second, MedSouth will monitor and analyze physician performance according to clinical practice guidelines and performance goals related to the quality and appropriate use of services. MedSouth maintains that the program will permit MedSouth physicians to improve patient care and outcomes, reduce medical errors, increase efficiency in the provision of services and reduce medical costs, and that it will discipline and terminate physicians who do not fully participate in the program and adhere to the program's standards.

Once its clinical program is operational, MedSouth proposes to market the services of its practice members to commercial third party payors, and to negotiate and execute contracts under which MedSouth members would provide services to health plan enrollees. All MedSouth members would be required to provide services under those contracts, and could not opt out. The physicians would not be precluded from participating in other networks or from contracting with payors independently if the payors did not contract with MedSouth.
The FTC staff opinion letter concluded that, based on the information provided by MedSouth, the group’s proposed collective negotiation and contracting with payors on behalf of its members should not be deemed per se illegal price fixing. The letter stated that the proposed program appears to be capable of creating substantial partial integration of the MedSouth physicians’ practices, and to have the potential to produce efficiencies in the form of higher quality or reduced costs for health care services provided by MedSouth physicians.

The letter also concluded that the collective negotiation of payor contracts appeared to be reasonably related to the integration, and to be reasonably necessary to the accomplishment of the program's objectives. On the facts presented, absent the assurance that the full panel of doctors would be involved in the network’s contracts, physicians were not likely to be willing to support integration activities on which efficiencies depended. Also, the opinion letter said, “joint contracting may permit the network to allocate the returns among members of the network in a way that creates incentives for the physicians to make appropriate investments of time and effort in setting up and implementing the proposed program.”

The opinion warned, though, that “mere adoption of a common clinical information system by itself, without the other programs that MedSouth intends to implement, would not suffice to establish that otherwise competing members of a physician network have integrated their practices in a manner or to an extent that
joint negotiation of prices could be deemed ancillary to an efficiency-enhancing joint venture.”

The staff letter warned that the MedSouth network would be closely monitored, and that absent a demonstration that the network had achieved significant efficiencies outweighing anti-competitive effects, enforcement action would likely be recommended if MedSouth’s physicians were able to use their collective power to force payors to contract with the network or to pay higher fees.

The letter relied on MedSouth’s representation that its physicians have been and will continue to contract individually with payors that wish to contract separately. If that were not to remain the case, the staff said, enforcement action could result, given the relatively high proportion of MedSouth physicians on the medical staffs of important hospitals in the Denver area.

A copy of the advisory opinion is available at http://www.ftc.gov/bc/adops/medsouth.htm

MESSENGER MODEL

Where there no risk-sharing or inadequate clinical integration, a physician network has the option of using the so-called "messenger model" to ameliorate risk of "price-fixing" problems. Under the messenger model, a network entity works out the basic content of a managed care contract, but does not negotiate or agree to price or price-related terms of dealing. That decision is left to

5 The network should be able to negotiate non-price and non-price related terms of a contract, unless the network poses a danger of exercise of market power in working out those
individual providers, to be effectuated through any of a number of contracting models.

DOJ has stated that a “properly implemented third-party messenger system, with adequate safeguards against collusion, should not lead to a messenger’s negotiating on behalf of competing independent physicians or enhance the bargaining leverage of such physicians.” A proper messenger model arrangement can “facilitate the contracting process, reduce transaction costs, and thus ultimately benefit consumers.” See *U.S. v. Federation of Physicians and Dentists, Inc.*, Civ. A. No. 98-475 (D. Del. Aug. 12, 1998) (complaint).

The FTC and DOJ Multiprovider Network Enforcement Policy Statement discusses the messenger model as follows (at pp. 125-27):

Messenger models can be organized and operate in a variety of ways. For example, network providers may use an agent or third party to convey to purchasers information obtained individually from the providers about the prices or price-related terms that the providers are willing to accept. In some cases, the agent may convey to the providers all contract offers made by purchasers, and each provider then makes an independent, unilateral decision to accept or reject the contract offers. In others, the agent may have received from individual providers some authority to accept contract offers on their behalf. The agent also may help providers understand the contracts offered, for example by providing objective or terms. Cf. FTC and DOJ Statement of Enforcement Policy on Providers' Collective Provision of Non-Fee-Related Information to Purchasers of Health Care Services (at 42) ("Providers who collectively threaten to or actually refuse to deal with a purchaser because they object to the purchaser's administrative, clinical, or other terms governing the provision of services run a substantial antitrust risk.") Note that an agreement on what some might consider to be a "non-price" term could be considered a "price" agreement in antitrust parlance, risking per se condemnation. See *Catalano, Inc. v. Target Sales, Inc.*, 446 U.S. 643 (1980) (per se price fixing rule applies to agreement among competitors to require advance or cash payment, and not to permit short term credit).
empirical information about the terms of an offer (such as a comparison of the offered terms to other contracts agreed to by network participants).

The key issue in any messenger model arrangement is whether the arrangement creates or facilitates an agreement among competitors on prices or price-related terms. Determining whether there is such an agreement is a question of fact in each case. The Agencies will examine whether the agent facilitates collective decision-making by network providers, rather than independent, unilateral, decisions. In particular, the Agencies will examine whether the agent coordinates the providers' responses to a particular proposal, disseminates to network providers the views or intentions of other network providers as to the proposal, expresses an opinion on the terms offered, collectively negotiates for the providers, or decides whether or not to convey an offer based on the agent's judgment about the attractiveness of the prices or price-related terms. If the agent engages in such activities, the arrangement may amount to a per se illegal price-fixing agreement.

Specific models for messenger model operation recognized in the policy statements are:

-- Messenger conveys payor's proposed price terms to network providers for their acceptance or rejection – contract could provide that provider will be deemed to have accepted or to have rejected if no response within specified time, or could require signature on terms.

-- Messenger uses “single signature” authority to “lock in” providers to payor contracts where price terms fall within price parameters individual providers have communicated to network – known sometimes as “accelerated messenger model” or “black box”. While the policy statements do not squarely address the possibility, there also appears to be room for an arrangement that lets the messenger make a judgment whether proposed price terms are substantially within parameters set by the provider in his or her private submission, for example, if provider has set out fees for ten common procedure codes and payor price schedule is within range for nine out of ten.

-- Messenger simply informs payors of individual price information provided by member providers. Messenger does not contract with payor.
On September 23, 2003, the FTC staff issued an advisory opinion approving a messenger model arrangement in California for the Bay Area Preferred Physicians organization. [http://www.ftc.gov/bc/adops/bapp030923.htm](http://www.ftc.gov/bc/adops/bapp030923.htm)

The arrangement was set up on an advance survey/physician commitment model. The guidance letter demonstrates that creativity and a desire to make the messenger model viable might have utility.\(^6\)

Some network organizations and consultants may have missed key limitations on messenger model contracting prior to 1996 and in some instances overreacted to the clarifications and flexibility afforded by the 1996 policy statements giving more explicit recognition to messenger model operations.

Seemingly common adaptations, risking antitrust dangers, have been:

- Applying “messenger model” label to arrangements where the network organization negotiates price, but then permits individual physician to “opt out”.

- Applying “messenger model” label where network organization establishes fee schedule as floor for any price proposal to be acceptable for presentation to network participants;

- Applying “messenger model” label to arrangements where network organization says it is not negotiating price with

---

\(^6\) The Department of Justice and Federal Trade Commission Bureau of Competition have each issued recent business advice letters giving a green light to provider groups seeking to conduct fee surveys. One planned to survey its members’ fee schedules and the other prices paid by payors, and both planned to publish the results. They each got favorable guidance, along with warnings to adhere to proper antitrust precautions to avoid boycotts and price fixing risks. Letter to Jerry B. Edmonds (re Washington State Medical Association), Sept. 23, 2002 [http://www.usdoj.gov/atr/public/busreview/200260.htm](http://www.usdoj.gov/atr/public/busreview/200260.htm) and FTC Bureau of Competition Letter to Greg Binford (re PriMed Physicians), Feb. 6, 2003, [http://www.ftc.gov/bc/adops/030206dayton.htm](http://www.ftc.gov/bc/adops/030206dayton.htm).
payor, but is actually is Network entity is hub of price conspiracy.

 pobl Network contracts with payors on the basis of a fee schedule or reimbursement formula produced by a hired consultant. Where parties to a joint venture could not lawfully agree among themselves on the prices they will charge to contracting payors, it does not solve antitrust issue to delegate decision on fees to "agent." Cartel cannot avoid antitrust risk by assigning price setting function to hireling.

Having "network" of providers approve contract, while individual providers must enter into separate contracts. If panel of individual physicians have effective voting rights to veto compensation terms proposed to individual doctors, price fixing risks can be significant. See Glen Eden Hospital v. Blue Cross and Blue Shield of Michigan, 740 F.2d 423 (6th Cir. 1984).

For some providers, it is not enough that existing law permits physicians to voice concerns on quality and similar issues, to form networks that are clinically or financially integrated to participate in managed care programs, or to gather and share data so that the contracting information gap is narrowed between physicians and payors, or to operate within the confines of the “messenger model”. Providers are pursuing a number of more aggressive responses.

Doctors in individual specialties are forming large “group practices without walls” to seek countervailing power. Some specialists are forming loose affiliations for joint managed care contracting. Traditional medical societies are

---

exploring whether union affiliations offer advantages, as are other medical organizations. The recent upturn in antitrust enforcement suggests that there may still be confusion about the applicable legal standards in the medical community, a lack of adequate deterrence against unlawful conduct, or possibly a lack of consensus on what the applicable legal standards really should be. The agencies would likely claim, though, that their cases, or at least most of them, are not at the cutting edge, are plowing little if any new ground in terms of antitrust law, and do not involve “close calls” on the facts.

Some antitrust observers have expressed the view that the messenger model is too cumbersome to be used efficiently, and that the agencies should soften their expressed position on physician network price agreements, in circumstances that make supracompetitive prices or an exercise of market power unlikely. Others are concerned that a more lenient formulation would encourage abusive conduct, that the per se rule retains value such that it should not be the government’s burden to provide market effects or market power when what it considers naked price fixing to be occurring. Still others have noted the odd circumstance of payors and providers sometimes seeking to work out mutually advantageous and arms-length deals, but having to worry whether the arrangements have enough indicia of integration to satisfy a third party reviewer.
Ultimately, neither risk sharing, clinical integration or the messenger model will permit full-scale cartel activity. If physician networks are interested in that, there is no room in the antitrust laws as they currently exist.

Today’s panel will focus on problems faced by the players in the marketplace and the response of the antitrust enforcement agencies, especially the FTC, to conduct that may cross the antitrust line.